Generic Medicine Info
Indications and Dosage
Pharyngitis, Tonsillitis
Adult: 500 mg once daily for 10 days.
Child: 2-12 years 7.5 mg/kg 12 hourly for 10 days. Max: 500 mg/dose; ≥13 years Same as adult dose.

Acute bacterial exacerbation of chronic bronchitis
Adult: 500 mg 12 hourly for 10 days.

Uncomplicated skin and skin structure infections
Adult: 250 or 500 mg 12 hourly, or 500 mg once daily. Treatment duration: 10 days.
Child: 2-12 years 20 mg/kg once daily. Max: 500 mg/dose; ≥13 years Same as adult dose.
Renal Impairment
CrCl Dosage
<30 Reduce dose by 50%.
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Add the amount of water as specified on the container in 2 equal portions to provide a susp containing 125 mg or 250 mg per 5 mL. Shake the bottle after each addition.
Hypersensitivity to cefprozil, or other cephalosporins.
Special Precautions
Patient with history of penicillin allergy, gastrointestinal disease (particularly colitis). Renal impairment. Pregnancy and lactation.
Adverse Reactions
Significant: Hypersensitivity, fungal or bacterial superinfection, including pseudomembranous colitis, Clostridium difficile-associated diarrhoea (prolonged use).
Gastrointestinal disorders: Diarrhoea, nausea, vomiting, abdominal pain.
Investigations: Increased serum transaminases.
Nervous system disorders: Dizziness.
Skin and subcutaneous tissue disorders: Diaper rash, genital pruritus.
Monitoring Parameters
Monitor renal function at baseline and as clinically indicated. Monitor for signs and symptoms of anaphylaxis during 1st dose.
Drug Interactions
May enhance the nephrotoxic effect of aminoglycosides. Increased serum concentrations with probenecid.
Lab Interference
Positive direct Coombs' test results. False-positive result in urine glucose determinations using cupric sulfate (e.g. Benedict's solution, Fehling's solution, Clinitest). False-negative result in ferricyanide test for blood glucose.
Description: Cefprozil is a semi-synthetic, broad-spectrum 2nd generation cephalosporin. It acts by inhibiting the bacterial cell wall synthesis by binding to 1 or more of penicillin-binding proteins (PBPs) which interrupts the final transpeptidation step of peptidoglycan synthesis leading to bacterial cell lysis and death.
Absorption: Well absorbed from the gastrointestinal tract. Bioavailability: 90-95%. Time to peak plasma concentration: 1.5 hours (fasting).
Distribution: Widely distributed in various body tissues and fluids. Enters breast milk. Volume of distribution: 0.23 L/kg. Plasma protein binding: Approx 36%.
Excretion: Via urine (approx 60%, as unchanged drug). Elimination half-life: 1-3 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Cefprozil, CID=5281006, https://pubchem.ncbi.nlm.nih.gov/compound/Cefprozil (accessed on Jan. 21, 2020)

Store between 20-25°C. Reconstituted powder for susp: Store between 2-8°C.
MIMS Class
ATC Classification
J01DC10 - cefprozil ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections.
Anon. Cefprozil. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 16/02/2022.

Anon. Cefprozil. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 06/01/2022.

Buckingham R (ed). Cefprozil. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/01/2022.

Cefprozil Powder for Suspension (Aurobindo Pharma Limited). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 06/01/2022.

Cefprozil Tablet, Film Coated (Aurobindo Pharma Limited). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 06/01/2022.

Cefzil Tablets 250 and 500 mg; Oral Suspension 125 mg/5 mL and 250 mg/5 mL (Bristol-Myers Squibb Company). U.S. FDA. https://www.fda.gov. Accessed 06/01/2022.

Disclaimer: This information is independently developed by MIMS based on Cefprozil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in